In this study, 81 patients with CAVD (60 patients with CFTR gene variants and 21 patients without CFTR or ADGRG2 gene variant) were treated with ICSI-ET/TESA (Fig. 1). The gene discussed is ADGRG2; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.